4.7 Article

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 12, Pages 5023-5038

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm401490p

Keywords

-

Funding

  1. Pfizer, Inc.

Ask authors/readers for more resources

The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available